European Headache Treatment Update

Day 7 (2023)

Video Preview

You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!

Key Questions

What is the difference between acute and preventive therapies for migraine?
Who is a candidate for migraine preventive treatment?
What is the difference between traditional migraine medications and the more novel CGRP inhibitors (Sometimes referred to as anti-CGRP medications)?
What types of traditional preventive therapies are readily available in Europe?
Are all migraine attacks driven by CGRP?
What is the mechanism of action behind the CGRP inhibitors (e.g., monoclonal antibodies, and gepants)?
What are the differences among the CGRP inhibitors currently available?
What CGRP monoclonal antibodies (mAbs) and CGRP receptor antagonists (gepants) are currently available in Europe?
Are ditans (selective 5HT1F receptor agonist) available in Europe?
What acute migraine treatments are currently available in Europe?
How can patients access the new CGRP Inhibitors in Europe?

Interview Notes

Treatments Mentioned

Amitriptyline
Analgesics (paracetamol)
Beta blockers
Botox
CGRP antibodies
NSAIDs
Steroids
Topiramate

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Expert

Patricia Pozo-Rosich, MD, PhD

Head of Neurology Section
Vall d’Hebron Hospital and Institute of Research, Spain

As the director of headache and neurological pain research at Vall d’Hebron Institute of Research in Barcelona, Spain, Dr. Pozo-Rosich is one of the leading migraine researchers in Europe. An active leader in the field of international headache medicine, Dr. Pozo-Rosich is passionate about educating patients and clinicians about migraine. She is the coordinator of the Headache Study Group of the Spanish Neurological Society (GECSEN). Additionally, she is the founder of the Spanish-language website MiDolordeCabeza.org. In 2023, she was awarded the Cephalalgia Award for her article “Salivary CGRP Can Monitor the Different Migraine Phases: CGRP (In)dependent Attacks,” which she presented at the International Headache Congress in Seoul, Korea.

Dr. Pozo-Rosich is a member of the International Headache Society, the American Headache Society, the International Headache Genetics Consortium, and the Catalan Neurological Society.